China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector
This article analyzed the new document about VBP for biosimilar drugs, diabetes drugs market, support devices market in interventional fields,...
399 Views
Kangji Medical IPO: Trading Debut
Kangji Medical (9997 HK) is the largest domestic minimally invasive surgical instruments and accessories (MISIA) platform in China, with a 2.7%...
540 Views
Kangji Medical (康基医疗) IPO Trading: Ample Upsides as Peer Performed Well
Kangji Medical raised HKD 2.9 billion (USD 381 m) from its global offering and will list on the stock exchange next Monday. In our previous...
572 Views
Kangji Medical IPO: Valuation Insights
Kangji Medical (1498779D CH) is the largest domestic minimally invasive surgical instruments and accessories (MISIA) platform in China, with a 2.7%...
447 Views
Kangji Medical (康基医疗) Pre-IPO: Superior Financial Metrics, Warrants a Premium
Kangji Medical is a domestic leader in minimally invasive surgery devices. It has three main product types, trocars, polymer ligation clips, and...
551 Views